This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The goal of the phase 3b STRIDE trial was to evaluate the safety of once-weekly injections of the GLP-1 receptor agonist semaglutide and to determine whether it improves function (symptoms and quality of life [QoL]) in patients with symptomatic peripheralarterydisease (PAD) and type 2 diabetes (T2D) with functional limitations.
Peripheralarterydisease (PAD) represents a significant global health burden, affecting >200 million people and accounting for approximately 10-15% of the population >50 years of age.
Semaglutide, compared to placebo, significantly improved walking distance, symptoms and quality of life in participants with symptomatic peripheralarterydisease (PAD) and type 2 diabetes (T2D), according to results of the STRIDE study presented at ACC.25
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Article 
68 
Let's personalize your content